- Statement on Second Circuit Order Upholding “Pharma Bro” Martin Shkreli’s Lifetime Ban ( )
- Statement Regarding Illumina’s Decision to Divest Grail ( )
- Statement Regarding the Termination of John Muir’s Takeover of San Ramon Regional Medical Center from Tenet Healthcare ( )
- FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge ( )
- Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug ( )
- FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens Sanofi’s Monopoly ( )
- FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings ( )
- FTC Sues to Block John Muir Health’s Takeover of San Ramon Regional Medical Center ( )
- FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book ( )
- FTC Sends Nearly $7 Million in Refunds to Consumers Harmed by Medical Discount Plans Sold as Health Insurance ( )
- FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’ ( )
- Statement Regarding Termination of CooperCompanies’ Attempted Acquisition of Cook Medical’s Reproductive Health Business ( )
- FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case ( )
- FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy ( )
- FTC Sues to Block IQVIA’s Acquisition of Propel Media to Prevent Increased Concentration in Health Care Programmatic Advertising ( )
- Federal Trade Commission Withdraws Health Care Enforcement Policy Statements ( )
- FTC Announces Tentative Agenda for July 20 Open Commission Meeting ( )
- FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market ( )
- FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law ( )
- FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices ( )
- FTC Staff Opposes State Legislation in North Carolina Designed to Shield UNC Health System from Antitrust Enforcement ( )
- FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop ( )
- Statement Regarding the Termination of Boston Scientific Corporation’s Attempted Acquisition of a Majority Stake in M.I. Tech Co., Ltd. ( )
- FTC Proposes Amendments to Strengthen and Modernize the Health Breach Notification Rule ( )
- FTC Deepens Inquiry into Prescription Drug Middlemen ( )
- Ovulation Tracking App Premom Will be Barred from Sharing Health Data for Advertising Under Proposed FTC Order ( )
- FTC Sues to Block Biopharmaceutical Giant Amgen from Acquisition That Would Entrench Monopoly Drugs Used to Treat Two Serious Illnesses ( )
- FTC Releases Agenda for May 18 Workshop on Proposed Changes to the Eyeglass Rule ( )
- FTC Sends 37 New Cease and Desist Letters Regarding Agency’s Eyeglass Rule ( )
- FTC Sues to Stop the Potentially Illegal Integration of New Orleans Area Hospitals Over Failure to Follow Federal Reporting Law ( )
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.